






jfw

<div>DEC 27 2004 PTO COMMUNICATIONS SECTION</div> TRANSMITTAL LETTER (General - Patent Pending)				Docket No. PC22038A/US	
In Re Application of: Allerton et al.					
Application No. 10/814,875	Filing Date March 31, 2004	Examiner Laura Stockton	Customer No. 26648	Group Art Unit 1626	Confirmation No. 8013
Title: 3-(IMIDAZOLYL)-2-AMINOPROPANOIC ACIDS					
<p style="text-align: center;"><u>COMMISSIONER FOR PATENTS:</u></p> <p>Transmitted herewith is:</p> <p style="padding-left: 40px;">Amendment Transmittal; Amendment and Response; Terminal Disclaimer; Itemized Postcard.</p> <p>in the above identified application.</p> <p><input checked="" type="checkbox"/> No additional fee is required.</p> <p><input type="checkbox"/> A check in the amount of _____ is attached.</p> <p><input checked="" type="checkbox"/> The Director is hereby authorized to charge and credit Deposit Account No. 19-1025 as described below.</p> <p style="padding-left: 40px;"><input type="checkbox"/> Charge the amount of _____</p> <p style="padding-left: 40px;"><input type="checkbox"/> Credit any overpayment.</p> <p style="padding-left: 40px;"><input checked="" type="checkbox"/> Charge any additional fee required.</p> <p><input type="checkbox"/> Payment by credit card. Form PTO-2038 is attached.</p> <p>WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.</p> <div> _____ Signature</div> <p>Daniel S. Kasten, Reg. No.45,363 Pharmacia Corporation of Pfizer Inc. P.O. Box 1027 Chesterfield, Missouri 63006 314.274.5218</p> <div><p>I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to the "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on December 21, 2004 (Date)  _____ Signature of Person Mailing Correspondence Linda K. Cooper _____ Typed or Printed Name of Person Mailing Correspondence</p></div> <p>cc:</p>					

AMENDMENT TRANSMITTAL LETTER (Large Entity)				Docket No. PC22038A/US	
Applicant(s): Allerton et al.					
Application No. 10/814,875	Filing Date March 31, 2004	Examiner Laura Stockton	Customer No. 26648	Group Art Unit 1626	Confirmation No. 8013
Invention: 3-(IMIDAZOLYL)-2-AMINOPROPANOIC ACIDS					
 COMMISSIONER FOR PATENTS:					
Transmitted herewith is an amendment in the above-identified application.					
The fee has been calculated and is transmitted as shown below.					
CLAIMS AS AMENDED					
	CLAIMS REMAINING AFTER AMENDMENT	HIGHEST # PREV. PAID FOR	NUMBER EXTRA CLAIMS PRESENT	RATE	ADDITIONAL FEE
TOTAL CLAIMS	1 -	106 =	0 x	\$50.00	\$0.00
INDEP. CLAIMS	1 -	3 =	0 x	\$200.00	\$0.00
Multiple Dependent Claims (check if applicable) <input type="checkbox"/>					\$0.00
TOTAL ADDITIONAL FEE FOR THIS AMENDMENT					\$0.00
<input checked="" type="checkbox"/> No additional fee is required for amendment. <input type="checkbox"/> Please charge Deposit Account No. _____ in the amount of _____ <input type="checkbox"/> A check in the amount of _____ to cover the filing fee is enclosed. <input checked="" type="checkbox"/> The Director is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account 19-1025 <input checked="" type="checkbox"/> Any additional filing fees required under 37 C.F.R. 1.16. <input checked="" type="checkbox"/> Any patent application processing fees under 37 CFR 1.17. <input type="checkbox"/> Payment by credit card. Form PTO-2038.					
WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.					
 _____ <i>Signature</i>			Dated: December 21, 2004		
Daniel S. Kasten, Reg. No. 45,363 Pharmacia Corporation of Pfizer Inc. P.O. Box 1027 Chesterfield, Missouri 63006 314.274.5218			I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on _____ December 21, 2004 (Date)  _____ Signature of Person Mailing Correspondence Linda K. Cooper _____ Typed or Printed Name of Person Mailing Correspondence		
cc:					

PC22038A-US



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RE APPLICATION OF: |

Allerton *et al.* |

GROUP ART UNIT: 1626


SERIAL NUMBER: 10/814,875 |

EXAMINER: L. Stockton

FILED: March 31, 2004 |

TITLE: 3-(IMIDAZOLYL)-2-AMINOPROPANOIC ACIDS

I hereby certify that this correspondence is being
deposited with the United States Postal Service as
First Class Mail in an envelope addressed to:
Commissioner for Patents, Mail Stop Patent Application,
Alexandria, VA 22313-1450,
on December 21, 2004
Linda K. Cooper

 Date: 12/21/2004

AMENDMENT AND RESPONSE

Commissioner for Patents,

Alexandria, VA 22313

Sir:

In response to the Office Action dated September 28, 2004, please enter
the following amendments and remarks.